Aliki Korkontzelou

Dr. Aliki Korkontzelou

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
SDStamatina Driva
Stamatina Driva
AKAliki Korkontzelou
Aliki Korkontzelou
STSerena Tonstad
Serena Tonstad
NTNikolaos Tentolouris
Nikolaos Tentolouris
paraskevi katsaounouparaskevi katsaounou
paraskevi katsaounou
Smokers with diabetes mellitus substantially lower their risks of microvascular and macrovascular diabetic complications, in particular cardiovascular disease, by quitting smoking. However, subsequent post-smoking-cessation weight gain may attenuate some of the beneficial effects of smoking cessation and discourage attempts to quit. Weight gain can temporarily exacerbate diabetes and deteriorate glycemic control and metabolic profile. The molecular mechanisms by which quitting smoking leads to weight gain are largely associated with the removal of nicotine’s effects on the central nervous system. This review addresses mechanisms of post-smoking-cessation weight gain, by reviewing the effects of nicotine on appetite, food intake, eating behaviour, energy expenditure, fat oxidation and appetite-regulating peptides. We also highlight correlations between post-cessation weight gain and risk of type 2 diabetes, consequences of weight gain in people with type 2 diabetes and the role of pharmacotherapies, which combine treatment of nicotine addiction and promotion of weight control.

23 March 2023 in Respiratory Medicine
Verified
Journal Article
Open access
KPKonstantinos Porpodis
Konstantinos Porpodis
Konstantinos BartziokasKonstantinos Bartziokas
Konstantinos Bartziokas
PCPanagiotis Chatziapostolou
Panagiotis Chatziapostolou
AKAliki Korkontzelou
Aliki Korkontzelou
PKPanos Katerelos
Panos Katerelos
Petros BakakosPetros Bakakos
Petros Bakakos
The extrafine single inhaler triple therapy (efSITT) containing beclometasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg has proved to be efficacious in patients with Chronic Obstructive Pulmonary Disease (COPD) in randomized control trials. TRIBUNE study aimed to assess the efSITT effectiveness on health status, lung function, adherence and rescue medication use in COPD patients in Greece in a real-world setting. This was a 24-week prospective, multicenter, observational study in 1,195 patients with moderate/severe COPD and history of at least one exacerbation during the previous year despite dual therapy. Health status (COPD Assessment Test/CAT), lung function parameters and rescue medication use were recorded at baseline, 3 (Visit 2/V2) and 6 months (Visit 3/V3) after treatment. Adherence (Test of Adherence to Inhalers/TAI) and self-reported overall impression of health condition change (Visual Analogue Scale/VAS) were recorded at V2 and V3. Mean CAT score decreased from 20.9 points at V1, to 15.1 at V2 and 13 at V3 (p < 0.001, all pair comparisons). 85.9% of patients achieved a CAT decrease of minimal clinically important difference (MCID) or more (≥2) at V3, compared to V1. Mean FEV1 increased from 1.4 ± 0.5 L on V1, to 1.6 ± 0.5 L on V3 (p < 0.001, N = 275). The percentage of patients with "good adherence" increased from 58.4% (V2) to 64.0% (V3). Rescue medication use and VAS also significantly improved. The efSITT achieves improved outcomes on health status, lung function and rescue medication use as well as satisfactory adherence and patient-reported improvement of health condition, in moderate/severe COPD patients previously treated with a dual combination in a Greek real-world setting.

17 August 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
SDStamatina Driva
Stamatina Driva
AKAliki Korkontzelou
Aliki Korkontzelou
STSerena Tonstad
Serena Tonstad
NTNikolaos Tentolouris
Nikolaos Tentolouris
ELEleni Litsiou
Eleni Litsiou
paraskevi katsaounouparaskevi katsaounou
paraskevi katsaounou
Background: Smoking cessation is crucial for reducing complications of type 2 diabetes mellitus (T2DM), but associated weight gain can worsen glycemic control, discouraging quitting attempts. Varenicline, a partial agonist of α4β2 nicotinic receptors, aids smoking cessation. This study examines the effects of varenicline on body weight and metabolic parameters in patients with T2DM and prediabetes. Methods: Fifty-three patients were enrolled, of which 32 successfully quit smoking after a three-month course of varenicline and were examined after an additional month with no medication. Measurements taken at baseline, 2.5 months, and 4 months included body weight, blood pressure, resting metabolic rate (RMR), glycated hemoglobin (HbA1c), fasting glucose, blood lipids, C-reactive protein (CRP), appetite-related hormones, and physical activity. Results: Post-treatment, there were no significant changes in body weight, blood pressure, RMR, or glycemic control. Total (CHOL) and low-density lipoprotein (LDL-C) cholesterol decreased significantly at 4 months of the study (from 168 to 156 mg/dL, p = 0.013, and from 96 to 83 mg/dL, p = 0.013, respectively). Leptin levels increased (from 11 to 13.8 ng/dL, p = 0.004), as did glucagon-like peptide-1 (GLP-1) levels (from 39.6 to 45.8 pM, p = 0.016) at 4 months of follow-up. The percentage of participants who reported moderate-intensity activity increased from 28% to 56%, while those reporting high-intensity activity increased from 19% to 22%, respectively (p = 0.039). Conclusions: Our study showed that smoking cessation with varenicline in smokers with T2DM and prediabetes led to significant improvements in lipid profile, significant increase in plasma leptin and GLP-1 levels, and increased physical activity, without significant weight gain. Thus, smoking cessation without weight gain or deteriorated glycemic control is feasible for these smokers, with added benefits to lipid profiles, GLP-1 regulation, and physical activity.

1 January 2024 in Therapeutic Advances in Respiratory Disease
Verified
Journal Article
Open access
PSPaschalis Steiropoulos
Paschalis Steiropoulos
NGNiki Georgatou
Niki Georgatou
GKGeorge Krommidas
George Krommidas
KBKonstantinos Bartziokas
Konstantinos Bartziokas
AKAliki Korkontzelou
Aliki Korkontzelou
KPKonstantinos Porpodis
Konstantinos Porpodis
Background: The extrafine single inhaler triple therapy (efSITT) containing beclomethasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg has proved to be efficacious in patients with chronic obstructive pulmonary disease (COPD) in randomized control trials. Objective: TRIWIN study evaluated the effectiveness of efSITT delivering beclomethasone dipropionate/formoterol fumarate/glycopyrronium 87/5/9 μg in COPD patients previously treated with multiple-inhaler triple therapy (MITT) in a real-world study in Greece. Design: Prospective, multicenter, observational, non-interventional study was conducted over 24 weeks. Methods: A total of 475 eligible patients had moderate-to-severe COPD, an indication for treatment with efSITT, and were symptomatic despite receiving MITT. COPD Assessment Test (CAT) score, pulmonary function parameters, use of rescue medication, and adherence to inhaler use were recorded at baseline (Visit 1), 3 (Visit 2), and 6 months (Visit 3) after treatment. Results: Mean CAT score decreased from 21.4 points at Visit 1, to 16.6 at Visit 2 and 15.1 at Visit 3 ( p < 0.001 for all pair comparisons). At Visit 3, 79.8% of patients reached a CAT improvement exceeding minimal clinically important difference (⩾2), compared to baseline. Mean forced expiratory volume in 1 s (%pred.) increased from 55.4% at Visit 1 to 63.5% at the end of study period ( p < 0.001), while mean forced vital capacity (%pred.) increased from 71.1% at Visit 1, to 76.7% at Visit 3 ( p < 0.001). The mean Test of Adherence to Inhalers score increased from 42.5 to 45.3 and 46.3 points, for the three visits, respectively ( p < 0.001 comparing Visits 1/2 and Visits 1/3; p = 0.006 comparing Visits 2/3). The percentage of patients showing good adherence rose from 33.7% at baseline to 58.3% at Visit 3. The percentage of patients using rescue medication during the last month dropped from 16.2% to 7.4% at the end of study period ( p < 0.001). Pulmonary function parameters also improved. Conclusion: The TRIWIN results suggest that extrafine beclomethasone dipropionate/formoterol fumarate/glycopyrronium is effective in improving health status, pulmonary function, and adherence and in reducing rescue medication use in COPD patients previously treated with MITT, in a real-world setting in Greece.

26 January 2023 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
JPJames G.H. Parkin
James G.H. Parkin
LDLaura Delgado-Ortiz
Laura Delgado-Ortiz
RDRosalie Delvert
Rosalie Delvert
MGManosij Ghosh
Manosij Ghosh
AKAliki Korkontzelou
Aliki Korkontzelou
ODOrianne Dumas
Orianne Dumas
In this article, early career members of the Epidemiology and Environment Assembly of the European Respiratory Society summarise a selection of five sessions from the Society's 2022 International Congress, with a focus on areas of specific interest for the Assembly,i.e.epidemiology and risk factors of respiratory diseases in both children and adults. Topics covered include the characterisation of obstructive respiratory diseases, their comorbidities and their evolution, with novel insight from large cohorts. The importance of early-life factors in respiratory health was also emphasised, including maternal exposures and habits during pregnancy. As smoking behaviours have changed following the introduction of e-cigarettes and heated tobacco products, research remains very active to determine the health consequences and predictors of these novel uses, especially in teenagers. The impact of environmental and occupational exposures on respiratory health remained a major topic of the congress, with a focus on emerging risk factors such as landscape fire smoke, non-exhaust particles and nanoparticles. Regarding workplace exposures, old and novel causes of occupational asthma and rhinitis were discussed.

7 September 2020 in European Respiratory Journal
Verified
Conference Paper
Closed access
ZBZafeiria Barmparessou
Zafeiria Barmparessou
AKAliki Korkontzelou
Aliki Korkontzelou
MIMarios Ioannou
Marios Ioannou
NVNikos Vichos
Nikos Vichos
MGMargarita Gkotsina
Margarita Gkotsina
PKParaskevi Katsaounou
Paraskevi Katsaounou
Introduction: Asthma attacks constitute a major cause of Emergency Room (ER) visits and a potential danger to patients9 life. Additionally, asthma exacerbations pose a severe economic burden for public health. Consequently, identifying the specific characteristics of this patient subgroup may lead to better patient management and subsequently less asthma attacks occurrence. Methods: Patients treated for an asthma exacerbation at the ER during four months (2019) were assessed for a definite asthma diagnosis at the outpatient clinic. The study included patients that the diagnosis of asthma was confirmed. Parameters reported at Figure 1a. Results: A total of 70 patients were enrolled, with 36,2% of them having an asthma diagnosis for the first time. Reexamination, carried out at least 3 months after the attack, revealed that the majority of patients had mild asthma. Specifically, 73,5% had stage I or II, 9,4% stage III and only 17% stage IV or V. Hospital admission occurred in 13,3% of patients (of which 50% stage I-II, 13% stage III and 37% of stage IV-V). Among patients with a previous diagnosis of asthma, prescribed medication included ICS-LABA (16,8%), ICS-LABA & LAMA (10%), SABA monotherapy (26,6%) whereas 30% did not receive any medication. 25,5% were exposed to passive smoking. Specific characteristics available at Figure 1b. Conclusion: The vast majority of patients with asthma attacks visiting ER were either not diagnosed for asthma or if they were diagnosed, they abused SABA and lacked proper medication. Most of them belong to stage II. Smoking, psychopathology, poor therapy adherence, lack of action plan and a new diagnosis where the most common characteristics.